Peptides for Muscle Hypertrophy: Maximizing Gains with Science-Based Protocols

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

This guide explores Selank and BPC-157 as adjunctive therapies for addiction recovery. Selank addresses anxiety and mood through GABAergic modulation, while BPC-157 supports physical healing and neuroprotection. Both peptides offer promising avenues for enhancing comprehensive, medically supervised addiction recovery programs.

# Peptides for Addiction Recovery: Selank, BPC-157, and the Opioid System

Introduction

Addiction is a complex, chronic disease with challenges in traditional treatments. Peptides, naturally occurring amino acid chains, offer novel therapeutic avenues. This guide explores Selank and BPC-157 as adjunctive therapies in addiction recovery, focusing on their mechanisms, clinical evidence, and interactions with the opioid system.

Selank: Mechanism of Action

Selank, a synthetic heptapeptide, enhances metabolic stability via a Pro-Gly-Pro sequence (Ashmarin et al., 2005; Ashmarin, 2007). It primarily modulates the GABAergic system as an allosteric GABA-A receptor modulator, similar to benzodiazepines but without their side effects (Volkova et al., 2016, PMID: 26924987; Seredenin et al., 1990, 1998). Selank modulates GABA binding (V\'yunova et al., 2014), alters neurotransmission-related gene expression (Volkova et al., 2016, PMID: 26924987), and normalizes dopamine metabolism under stress, preventing prefrontal cortex depletion. These actions contribute to its anxiolytic, antidepressant, and neuroprotective properties, making it a candidate for addiction\'s psychological and neurological aspects.

Selank: Clinical Evidence & Research

Selank consistently shows anxiolytic and neuroprotective properties, managing anxiety and stress in addiction recovery. It offers comparable anxiolytic activity to low-dose benzodiazepines but without dependence or withdrawal (Seredenin et al., 1990, 1998). Kasian et al. (2017, PMID: 28280289) found Selank reduced anxiety in stressed rats; combined with diazepam, it enhanced anxiolytic effects, potentially allowing lower benzodiazepine doses. Clinical observations show Selank\'s efficacy similar to medazepam and phenazepam for anxiety disorders, without typical benzodiazepine side effects (Zozulia et al., 2008, PMID: 18454096). Combining Selank with phenazepam also improved therapeutic effects and reduced side effects (Medvedev et al., 2015, PMID: 26176481), enhancing anxiety management in addiction recovery.

Selank: Dosing Protocol

Human dosing protocols for Selank in addiction recovery are still evolving and require professional medical guidance. Preclinical studies suggest intranasal administration is optimal for CNS delivery, bypassing digestion and enhancing bioavailability (Zolotarev et al., 2006; Ashmarin et al., 2008). Rat studies identified an effective anxiolytic dose of 300 µg/kg intranasally (Seredenin et al., 1998; Kozlovskaya et al., 2003). For human use, anecdotal and clinical contexts report typical intranasal dosages from 200 µg to 1 mg per day, often divided, with varying durations (e.g., 10-14 day cycles). Selank is not FDA-approved in many Western countries; its use requires caution and strict medical guidance. Intranasal administration is preferred for direct brain access, though subcutaneous injection is also possible. Precise dosing and supervised protocols are essential. Always consult a qualified healthcare provider before starting any peptide protocol.

Selank: Benefits & Expected Results

Selank offers several benefits for addiction recovery, primarily through its anxiolytic, neuroprotective, and mood-stabilizing effects, which are crucial for sustained sobriety.

Anxiety Reduction: Selank reduces anxiety without the sedative effects, cognitive impairment, or dependence risk of traditional anxiolytics. This is vital in early recovery, where anxiety and stress trigger relapse. Users may experience calmness, reduced apprehension, and improved emotional regulation.

Mood Stabilization: Its antidepressant and antistress properties stabilize mood by normalizing dopamine metabolism and modulating GABAergic activity, alleviating depression and improving stress resilience.

Cognitive Enhancement: Selank exhibits nootropic actions, improving memory and learning (Kost et al., 2001; Sokolov et al., 2002), which aids therapy, skill-building, and reintegration.

Neuroprotection: By modulating gene expression and offering general neuroprotection, Selank can mitigate neurological damage from substance abuse, supporting brain healing.

Expected Results and Timeline: Effects vary, but some users report anxiety and mood improvements within days to a week, with full therapeutic effects appearing after several weeks. Benefits include improved well-being, sleep, focus, and stress coping. Its lack of withdrawal symptoms makes it favorable for long-term support. Individual responses differ, requiring healthcare professional monitoring.

Selank: Side Effects & Safety

Selank generally has a favorable safety profile compared to conventional anxiolytics, designed to provide benefits without benzodiazepine drawbacks. Most reported side effects are mild and transient, including mild irritation at the intranasal administration site, transient fatigue or drowsiness, and infrequent headaches.

A key advantage is the absence of severe benzodiazepine-like side effects: no amnesia, cognitive impairment, physical dependence, withdrawal syndrome, or rapid tolerance development. This makes it a safer option for long-term use in recovery.

Contraindications and Precautions: Selank is generally contraindicated during pregnancy and breastfeeding due to insufficient research. Its safety in children is not established. Caution is advised when combining with other CNS-active medications due to potential additive effects, even with suggested synergistic effects with diazepam, which requires strict medical supervision. Individuals with severe liver or kidney impairment or other serious medical conditions should consult their healthcare provider. Always consult a qualified healthcare provider before starting any peptide protocol to ensure appropriateness and manage risks.

BPC-157: Mechanism of Action

Body Protective Compound-157 (BPC-157) is a synthetic pentadecapeptide from human gastric juice protein BPC. It\'s known for regenerative and cytoprotective properties, influencing systemic physiological processes relevant to addiction recovery and the opioid system (Sikiric et al., 2013, 2018, 2020a, b).

BPC-157 modulates the nitric oxide (NO) system, crucial for vascular integrity, inflammation, and neurotransmission. This contributes to cytoprotective effects and cell survival, including in the brain (Sikiric et al., 2021, PMID: 34380875).

It promotes angiogenesis and collagen production for tissue regeneration and wound healing by upregulating growth factors (VEGF, bFGF) and influencing gene expression (Huang et al., 2015, PMID: 25969618; Hsieh et al., 2017, PMID: 27933402). These regenerative effects extend to neurological tissues, supporting neuronal survival and recovery.

BPC-157 significantly impacts the CNS and neurotransmitter systems, including dopaminergic and opioid pathways, relevant for addiction recovery. It counteracts dopamine system disturbances, modulating receptor sensitivity and preventing nigrostriatal damage (Sikiric et al., 2021, PMID: 34380875), addressing addiction\'s dopamine dysregulation and craving.

BPC-157 interacts with the opioid system, counteracting morphine-induced analgesia and influencing tolerance/dependence to substances like diazepam (Jelovac et al., 1999a, PMID: 10478980; Jelovac et al., 1999b, PMID: 10478980). It may modulate opioid receptor activity or signaling, potentially mitigating withdrawal and reducing opioid reinforcing effects. Its cytoprotective, regenerative, and neurotransmitter-influencing actions highlight its multifaceted potential in addiction recovery.

BPC-157: Clinical Evidence & Research

Extensive animal research on BPC-157 shows broad benefits in tissue repair, anti-inflammatory effects, and GI health, suggesting therapeutic potential for addiction recovery.

Neuroprotective and CNS Effects: Vukojević et al. (2021, PMID: 34380875) reviewed BPC-157\'s CNS effects, noting it counteracts stroke-induced brain damage, resolves memory/coordination issues, and supports hippocampal gene expression. This neuroprotection is vital in addiction, where substance abuse causes neuronal damage and cognitive deficits.

Dopamine System Modulation: BPC-157 counteracts dopamine system disturbances in addiction, reversing amphetamine-induced issues, haloperidol-induced catalepsy, and modulating dopamine receptor sensitivity (Sikiric et al., 2021, PMID: 34380875), addressing reward pathway dysregulation and cravings.

Opioid System Interaction: BPC-157 interacts with the opioid system, counteracting morphine-induced analgesia (Jelovac et al., 1999a, PMID: 10478980) and influencing tolerance/dependence to drugs like diazepam (Jelovac et al., 1999b, PMID: 10478980). Preclinical findings suggest potential to alleviate withdrawal and reduce relapse risk in opioid addiction, though human trials are limited.

Anti-inflammatory and Regenerative Properties: BPC-157\'s anti-inflammatory and regenerative capabilities benefit chronic substance abuse, which causes systemic inflammation and tissue damage. It promotes healing in GI tract (Sikiric et al., 2013, PMID: 23844948) and musculoskeletal system (Seiwerth et al., 2018, PMID: 29998800), supporting overall physiological recovery in addiction treatment.

Though most evidence is from animal studies, BPC-157\'s consistent, broad therapeutic effects warrant further human clinical trials for addiction recovery. Always consult a qualified healthcare provider before starting any peptide protocol.

BPC-157: Dosing Protocol

Human dosing protocols for BPC-157 in addiction recovery are not standardized and require professional medical guidance. Not FDA-approved in many regions, its use demands caution and supervision. Preclinical research and anecdotal reports offer insights into potential dosing strategies.

Routes of Administration: BPC-157 can be administered via several routes:

Subcutaneous/Intramuscular Injection: Common for systemic effects, general healing, and anti-inflammatory benefits. Doses typically range from 200 µg to 500 µg per day.

Oral Administration: Viable for gastrointestinal issues due to gastric acid stability. Doses can range from 250 µg to 1 mg per day.

Intranasal Administration: Used for CNS effects, with doses similar to subcutaneous routes.

Mild pain or irritation at the injection site: For subcutaneous or intramuscular administration, some localized discomfort, redness, or swelling may occur.

Nausea or digestive upset: Although BPC-157 is known for its gut-healing properties, a small number of individuals might experience mild digestive disturbances, especially with oral administration.

Fatigue: Some users have reported transient fatigue, particularly during the initial days of use.

Lack of Significant Toxicity: Extensive preclinical research has consistently shown BPC-157 to be non-toxic, even at high doses. It does not appear to induce adverse effects on major organ systems, nor does it exhibit mutagenic or carcinogenic properties. This excellent safety record in animal models is a key reason for its growing interest.

Contraindications and Precautions:

Pregnancy and Breastfeeding: As with many peptides, there is insufficient data on the safety of BPC-157 during pregnancy and breastfeeding. Therefore, its use is generally not recommended in these populations.

Children: The safety and efficacy of BPC-157 in children have not been established.